Worldwide Clinical Trials announced Clare Wallis has joined as senior vice president. Under Wallis’ guidance, the global team will work in partnership with oncology sponsors to support their clinical development objectives from early phase studies to large global registrational programs.
Wallis joins Worldwide’s deep bench of seasoned oncology experts, bringing 23 years of experience developing global operational and clinical teams that can navigate the nuances of designing and executing a successful, tailored clinical trial. Wallis has helped sponsors execute clinical trials in gene therapy, immuno-oncology and novel targeted therapies, among others. Prior to joining Worldwide, she served as vice president of project management, feasibility and advocacy at Synteract, US (recently acquired by Syneos Health), and held several roles with increasing responsibility at Chiltern, ICON, Orion CRO and Covance.
“This work is personal for me,” said Wallis. “Like many on the Worldwide team and across the globe, I’ve experienced the impact that cancer can have on individuals and families. The opportunity to lead a dedicated team that is passionate about oncology research is inspiring. We stand ready to tackle the most complex trials and achieve our shared goal of bringing new options and potentially breakthrough treatments for cancer patients.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“To overcome the growing complexities of clinical trials, sponsors need a nimble team of experts who can advise them on not only the ingredients for a successful trial but also what will make their trial successful,” said Peter Benton, president and chief operating officer, Worldwide Clinical Trials. “Clare has extensive experience bringing together global experts to ensure that trials rise to their unique challenges. Her highly consultative and collaborative philosophy mirrors Worldwide’s adaptive approach to helping biopharma and biotech sponsors overcome hurdles for conclusive studies – no matter how complex.”